svb.com

Outlet metrics

Domain Authority

Ranking

Global

#84485

United States

#24386

Finance/Finance

#343

Traffic sources

Monthly visitors

Articles

Digital banking platform | SVB Go

1 month ago | svb.com

The online portal that thousands of founders and finance teams use to manage cash, issue payments, and gain insights every day.
US Climate Tech Investment Achieves Six Straight Months of Growth; Silicon Valley Bank Releases Annual Report

2 months ago | svb.com

The climate tech sector is seeing signs of recovery as venture capital (VC) is flowing into energy, manufacturing, and carbon tech, according to the latest report from Silicon Valley Bank. Additionally, Climate tech funds are outperforming overall VC, reaching a 9% higher internal rate of return (IRR) in the 2020-2024 fund vintage.
Funding challenges for life science and healthcare startups

2 months ago | svb.com | Michael Ritter |Tim Lew

Early-stage life science and healthcare founders face fundraising challenges. Learn how trusted partners and non-dilutive funding can help overcome these hurdles.
Evolving your cybersecurity due diligence process

Feb 4, 2025 | svb.com | Anthony Dagostino

Third-party vendors and AI tools can be overlooked vectors for potential cybersecurity threats.
Healthcare Investments and Exits Mid-Year Report

Jan 8, 2025 | svb.com

SVB’s Healthcare Investments and Exits mid-year report for 2024 examines fundraising and venture capital trends in the life science and healthcare industry and the biopharma, healthtech, diagnostics/tools, and device sectors.
Venture Capital Fundraising in Healthcare Remains Healthy; Silicon Valley Bank Releases 15th Edition of Healthcare Investments and Exits Report

Jan 8, 2025 | svb.com

Venture Capital investment in healthcare grew to $23 billion in 2024, from $20 billion in 2023, as artificial intelligence clearly established product fit in the healthcare sector, according to the latest market insights report from Silicon Valley Bank (SVB), a division of First Citizens Bank. AI continues to take center stage, especially across biopharma, with 30% of healthcare investment in 2024 going to companies leveraging AI.
Three technologies transforming crypto in 2025 | Silicon Valley Bank

Jan 1, 2025 | svb.com | Anthony Vassallo |Josh Pherigo

Find out how we expect payments, AI and gaming will accelerate crypto adoption in 2025. Drawing from our proprietary data, industry insights and global data, SVB’s experts explore the current and future crypto market.
Fintech Sector Investment Remains Muted While Opportunity Persists in 2024; Silicon Valley Bank Releases Fourth Edition of Future of Fintech Report

Oct 23, 2024 | svb.com

While fintech companies face significant headwinds – from high interest rates to increasing regulatory oversight – they are also finding opportunity in 2024, according to the latest Future of Fintech Report from Silicon Valley Bank (SVB), a division of First Citizens Bank. Venture capital (VC) investment remains muted, hovering near a six-year low for the sector, as deal flow has shifted toward the early stage, with more than three seed deals for every one series A. Artificial intelligence (AI) is also emerging as a bright spot for the industry as investors and founders explore its growing role in the sector.
Healthtech Sector Investment Shows Resilience and Early Recovery in 2024; Silicon Valley Bank Releases Fifth Edition of Future of Healthtech Report

Oct 16, 2024 | svb.com

The healthtech sector is experiencing a recalibration in valuations, as the industry is showing signs of early recovery with investments stabilizing and artificial intelligence (AI) driving new growth, according to the 2024 Future of Healthtech Report from Silicon Valley Bank (SVB), a division of First Citizens Bank. Despite ongoing market volatility and macroeconomic uncertainty, healthtech investment in 2024 is on a positive trajectory, hovering between $4.0 billion and $4.5 billion per quarter and surpassing pre-pandemic levels.
Non-dilutive capital for biotech startups, Part 3

Sep 17, 2024 | svb.com | Anton Xavier

The third part of the series on non-dilutive funding options looks at ARPA-H for biotech startups. In this article, best practices are shared on how biotech companies can best navigate these funding sources, and how to better prepare for applying.